West Pharmaceutical Services (WST) Cash from Financing Activities (2009 - 2026)

West Pharmaceutical Services has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$308.7 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$308.7 million, down 110.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$346.8 million (up 30.45% YoY), and the FY2025 annual result was -$185.1 million, up 70.27% from the prior year.
• Cash from Financing Activities came in at -$308.7 million for Q1 2026 at West Pharmaceutical Services, down from -$11.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of -$9.5 million in Q4 2022 to a low of -$308.7 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$71.0 million (2023), against an average of -$110.0 million.
• Across the five-year window, Cash from Financing Activities plunged 12166.67% in 2022 and soared 93.17% in 2025, its largest moves.
• West Pharmaceutical Services' Cash from Financing Activities stood at -$9.5 million in 2022, then slumped by 1894.74% to -$189.5 million in 2023, then surged by 63.64% to -$68.9 million in 2024, then jumped by 83.02% to -$11.7 million in 2025, then plunged by 2538.46% to -$308.7 million in 2026.
• The last three Cash from Financing Activities figures came in at -$308.7 million (Q1 2026), -$11.7 million (Q4 2025), and -$11.5 million (Q3 2025), per Business Quant data.